Navigation Links
SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
Date:12/9/2008

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that results from a Phase I clinical trial of a DNA vaccine for severe acute respiratory syndrome (SARS), conducted by the National Institutes of Health (NIH) and published in the November 25 issue of Vaccine(1), demonstrated that the vaccine was well-tolerated, and induced neutralizing antibody responses in 80% of the vaccinees and T-cell immune responses in all vaccinees. The Phase I trial was initiated with unprecedented speed, within 19 months of the publication of the SARS coronavirus genetic sequence from which the vaccine was derived, and was the first SARS vaccine human clinical trial conducted in the United States.

The DNA vaccine was developed by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), NIH, and manufactured by Vical. Three doses of 4 mg each were delivered on Days 0, 28 and 56 with the Biojector(R) 2000 needle-free injection system (Bioject Medical Technologies Inc., OTC Bulletin Board: BJCT). In the article, authors from the VRC detailed safety and immunogenicity results, and concluded, "This vaccine also demonstrates the feasibility of rapid manufacturing and regulatory review and provides additional safety and immunogenicity data to support the concept of DNA vaccination as a potential vaccine platform for future emerging infectious diseases."

After completion of the NIH Phase I clinical trial, NIAID transferred the Investigational New Drug application (IND) for the vaccine to Vical, and the company has evaluated its options to continue development of the vaccine when a medical need arises. "Like many emerging infectious diseases, SARS is suspected of having origins in an animal reservoir and is therefore likely to re-emerge at some point in the future," sa
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa
2. Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
3. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
4. The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Countrys Biological Preparedness
5. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
6. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
7. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
8. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
9. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
10. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
11. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... amniotic tissue and patent-protected processes to develop and ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and ... the multiple inaccuracies in the press release issued ... recent rulings from the Patent Trial and Appeal ...
(Date:8/27/2015)...  Hill-Rom Holdings, Inc., (NYSE: HRC ) invites ... Morgan Stanley Global Healthcare Conference on September 16, 2015, ... to listen to the live discussion via the internet ... https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded replay of ... conclusion of the live event and accessible via the ...
(Date:8/27/2015)... -- Major pharmaceutical and medical device companies and leading law ... Philadelphia on Oct. 20, discussing issues surrounding ... of HB Litigation Conferences has announced. To ... http://litigationconferences.com/?p=31886 The program is co-chaired by ... Michelle Hart Yeary of Dechert LLP. ...
Breaking Medicine Technology:MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3
... The World Health Organization (WHO) has granted prequalification to ... immunization of infants and children from 6 weeks through ... otitis media caused by the 13 pneumococcal serotypes (1, ... 19A, 19F and 23F) contained in the vaccine. WHO ...
... Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS ; ... financial results for the fiscal 2010 fourth quarter and year ... August 30, 2010. Management has scheduled a ... 30, 2010 (Tuesday, August 31 at 6.30 a.m. AEST) ...
Cached Medicine Technology:World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 2World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 3World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 4World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 5World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 6World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 7Unilife Corporation Schedules Fiscal 2010 Fourth Quarter and Year End Conference Call for Monday, August 30, 2010 2
(Date:8/27/2015)... ... 2015 , ... In an article published July 30th by the ... New Orleans, highlighting a security firm that is tasked with providing supplemental protection. Called ... who worked with the city to provide private security when it is needed in ...
(Date:8/27/2015)... ... August 27, 2015 , ... Allegheny General Hospital (AGH), part ... medical centers in the United States to receive international recognition for an advanced, ... Extracorporeal Life Support Organization (ELSO) , an international consortium of healthcare institutions dedicated ...
(Date:8/27/2015)... Michigan (PRWEB) , ... August 27, 2015 , ... On ... returned for the second year as sponsor of the “Music With A Mission” benefit ... raise money for music education programs in the underfunded school districts of Mendon and ...
(Date:8/27/2015)... ... 27, 2015 , ... Dr. Jennifer Arnold, co-star of “The Little Couple” and ... 3rd Annual MPN Heroes™ recognition event on Friday, Dec. 4, prior to ... honoring eight heroes who have made significant contributions in the field of rare blood ...
(Date:8/27/2015)... ... August 27, 2015 , ... Infocast is ... October 27-29, 2015 in San Jose, CA. The first event dedicated to ... the void that exists where battery development and energy storage innovation are concerned. ...
Breaking Medicine News(10 mins):Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2
... 1960s, surgeons experimented by transplanting chimpanzee organs into humans in ... a baboon heart and survived 20 days. Since then, doctors// ... organs, tissues and cells to treat various diseases, all with ... surrounding cross-species transplant -- also known as xenotransplantation. ...
... common treatment option for HIV patients is associated with ... a new study. However, researchers say the benefit of ... for most patients. ,Combination antiretroviral therapy substantially ... AIDS. Before this therapy was available, the annual mortality ...
... for centuries, doctors say. But only recently has it been ... migraines or neck- and head-squeezing tension headaches //that are present ... think it sounds like just another excuse to skip school. ... freshman from St. Cloud, Minnesota, know how serious the condition ...
... is a common health problem worldwide. Both osteoarthritis and ... There is no cure for arthritis and no effective ... study could help lead doctors towards a drug to ... molecular pathway and an enzyme that play a pivotal ...
... caused a recent outbreak of Hepatitis A in Pennsylvania ... ,Bill Zavertnik, Chi-Chi's chief operating officer, said in ... were not the source of the outbreak, that there ... outbreak and that it was an isolated incident. , ...
... new study shows a new drug alternative to warfarin in ... The research shows the drug ximelagatran appears to be as ... for people at high risk of stroke because of its ... include an increased risk of bleeding and a possible interaction ...
Cached Medicine News:Health News:Animals can give us a second chance at life 2Health News:HIV Treatment Said to Increase Heart Attack Risk 2Health News:Finding relief from Excruciating Headaches a challenge 2Health News:Finding relief from Excruciating Headaches a challenge 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: